Trending

ulcerative colitis

AbbVie/Allergan merger cleared in EU with brazikumab sell-off

AbbVie/Allergan merger cleared in EU with brazikumab sell-off

AbbVie and Allergan’s $63 billion merger has been cleared by European regulators, who have approved the sell-off of

X

AbbVie/Allergan merger cleared in EU with brazikumab sell-off

https://pharmaphorum.com/news/abbvie-allergan-merger-cleared-in-eu-with-brazikumab-sell-off/

AZ buys back rights to Crohn’s candidate from Allergan, ahead of AbbVie merger

AZ buys back rights to Crohn’s candidate from Allergan, ahead of AbbVie merger

Allergan is selling rights to its Crohn’s disease drug brazikumab back to AstraZeneca in a move to satisfy

X

AZ buys back rights to Crohn’s candidate from Allergan, ahead of AbbVie merger

https://pharmaphorum.com/news/az-buys-back-rights-to-crohns-candidate-from-allergan-ahead-of-abbvie-merger/

J&J gets Stelara okay in Europe for ulcerative colitis

J&J gets Stelara okay in Europe for ulcerative colitis

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new

X

J&J gets Stelara okay in Europe for ulcerative colitis

https://pharmaphorum.com/news/jj-gets-stelara-okay-in-europe-for-ulcerative-colitis/

Allergan says it will shed two drugs as AbbVie takeover looms

Allergan says it will shed two drugs as AbbVie takeover looms

Allergan has confirmed that it will divest experimental inflammatory bowel disease therapy brazikumab and marketed drug Zenpep ahead

X

Allergan says it will shed two drugs as AbbVie takeover looms

https://pharmaphorum.com/news/allergan-says-it-will-shed-two-drugs-as-abbvie-takeover-looms/

Takeda’s Entyvio outperforms AbbVie’s Humira in GI trial

Takeda’s Entyvio outperforms AbbVie’s Humira in GI trial

Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard –

X

Takeda’s Entyvio outperforms AbbVie’s Humira in GI trial

https://pharmaphorum.com/news/takedas-entyvio-outperforms-abbvies-humira-in-gi-trial/

New data sets up potential new gastro use for J&J’s Stelara

New data sets up potential new gastro use for J&J’s Stelara

Janssen’s Stelara has shown positive results in an ulcerative colitis (UC) trial, setting up a potential new indication

X

New data sets up potential new gastro use for J&J’s Stelara

https://pharmaphorum.com/news/new-data-sets-up-potential-new-gastro-use-for-jjs-stelara/

Abivax sets its course on colitis and Crohn’s

Abivax sets its course on colitis and Crohn’s

French biotech moves on with the late stage drug development, after publishing impressive clinical trial results of ABX464

X

Abivax sets its course on colitis and Crohn’s

https://pharmaphorum.com/news/abivax-scolitis-crohns/

FDA approves oral treatment for ulcerative colitis

FDA approves oral treatment for ulcerative colitis

Pfizer’s janus kinase (JAK) inhibitor drug Xeljanz (tofacitinib) has received expanded approval from the FDA for adults with moderately-to-severely-active ulcerative colitis.

X

FDA approves oral treatment for ulcerative colitis

https://pharmaphorum.com/news/fda-oral-treatment-ulcerative-colitis/

Janssen inks potential $1bn deal for IBD drug

Janssen has swooped to buy rights to an early-stage oral inflammatory bowel disease drug from Protagonist Therapeutics in

X

Janssen inks potential $1bn deal for IBD drug

https://pharmaphorum.com/news/janssen-inks-potential-1bn-deal-ibd-drug/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com